Bison Capital Partners V, LP has announced the sale of Apex Innovative Sciences, Inc.

SANTA MONICA, CA (June 16, 2022) – Bison Capital Partners V, LP (“Bison Capital”) has announced the sale of Apex Innovative Sciences, Inc. (“Apex” or the “Company”) to CenExel Clinical Research, Inc. (“CenExel”). Apex is the industry-leading independent operator of clinical trial sites focused on complex clinical trial studies for central nervous system (“CNS”) indications. Apex was formed in 2019 in conjunction with Bison Capital’s investment and the merger of CNS Network and Hassman Research Institute, complemented by the acquisition of Clinical Trial Centers Alliance, a leading coordinator of clinical trial site studies for sponsors and clinical research organizations.

Download Full Press Release

About Apex Innovative Sciences, Inc.

Apex Innovative Sciences, Inc. is a global provider of clinical development and site services. Apex represents the consolidation of core businesses including Hassman Research Institute, CNS Network and Clinical Trial Centers Alliance. The expanded team collaborates to provide quality, efficiency, and value in the development of innovative medicines. Apex helps sponsors achieve go/no‐go decisions, reduce development costs, and deliver high quality results. Apex is committed to providing scientific, technological, and organizational expertise in Phase I‐IV clinical trials, including Neurology, Psychiatry, Addiction, Asian Bridging, Pain, Healthy Subjects and General Medicine. The company prides itself on delivering the highest scientific and clinical quality for its client partners and participants.


Bison Capital is a Los Angeles and New York based private equity firm that makes growth capital investments in middle‐market companies, public or private, for expansion, acquisitions, and balance sheet recapitalizations. The firm’s primary investment focus is partnering with entrepreneurs and management teams seeking capital to grow their businesses.